- Home
- TECX vs CHAC Comparison
TECX vs CHAC Comparison
Compare TECX & CHAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TECX
- CHAC
- Stock Information
- Founded
- TECX 2019
- CHAC 2025
- Country
- TECX United States
- CHAC United States
- Employees
- TECX N/A
- CHAC N/A
- Industry
- TECX
- CHAC
- Sector
- TECX
- CHAC
- Exchange
- TECX Nasdaq
- CHAC NYSE
- Market Cap
- TECX 334.4M
- CHAC 300.0M
- IPO Year
- TECX 2018
- CHAC 2025
- Fundamental
- Price
- TECX $21.09
- CHAC $10.02
- Analyst Decision
- TECX Buy
- CHAC
- Analyst Count
- TECX 6
- CHAC 0
- Target Price
- TECX $78.67
- CHAC N/A
- AVG Volume (30 Days)
- TECX 243.5K
- CHAC 11.3K
- Earning Date
- TECX 08-13-2025
- CHAC 01-01-0001
- Dividend Yield
- TECX N/A
- CHAC N/A
- EPS Growth
- TECX N/A
- CHAC N/A
- EPS
- TECX N/A
- CHAC N/A
- Revenue
- TECX N/A
- CHAC N/A
- Revenue This Year
- TECX N/A
- CHAC N/A
- Revenue Next Year
- TECX N/A
- CHAC N/A
- P/E Ratio
- TECX N/A
- CHAC N/A
- Revenue Growth
- TECX N/A
- CHAC N/A
- 52 Week Low
- TECX $13.70
- CHAC $9.98
- 52 Week High
- TECX $61.07
- CHAC $11.28
- Technical
- Relative Strength Index (RSI)
- TECX 50.45
- CHAC N/A
- Support Level
- TECX $19.13
- CHAC N/A
- Resistance Level
- TECX $20.75
- CHAC N/A
- Average True Range (ATR)
- TECX 1.33
- CHAC 0.00
- MACD
- TECX -0.10
- CHAC 0.00
- Stochastic Oscillator
- TECX 56.73
- CHAC 0.00
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
About CHAC CRANE HBR ACQUISITION CORP
Crane Harbor Acquisition Corp is a blank check company.